Endothelial dysfunction in coronary heart disease is more than a systemic process

European Heart Journal

Volumn 34, Issue 27, 2013, Pages 2025-2027

  Ganz, Peter ^a   Hsue, Priscilla Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; DRUG INDUSTRY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HEMODYNAMIC STRESS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NEAR INFRARED SPECTROSCOPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SHEAR STRESS; STABLE ANGINA PECTORIS;

CORONARY STENOSIS; FEMALE; HUMANS; LIPID METABOLISM; MALE; PLAQUE, ATHEROSCLEROTIC;

EID: 84880567329     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht199     Document Type: Review

References (17)

1. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051. (Pubitemid 17170620)
2. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Luscher TF, Shechter M, Taddei S, Vita JA, Lerman A. The assessment of endothelial function: from research into clinical practice. Circulation 2012;126: 753-767.
3. Ganz P, Vita JA. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 2003;108:2049-2053. (Pubitemid 37337576)
4. Ku IA, Imboden JB, Hsue PY, Ganz P. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J 2009;73:977-985
5. Ganz P, Hsue PY. Individualized approach to the management of coronary heart disease: identifying the nonresponders before it is too late. J Am Coll Cardiol 2009; 53:331-333.
6. Charakida M, Masi S, Loukogeorgakis SP, Deanfield JE. The role of flow-mediated dilatation in the evaluation and development of antiatherosclerotic drugs. Curr Opin Lipidol 2009;20:460-466,
7. Shenouda SM, Widlansky ME, Chen K, Xu G, Holbrook M, Tabit CE, Hamburg NM, Frame AA, Caiano TL, Kluge MA, Duess MA, Levit A, Kim B, Hartman ML, Joseph L, Shirihai OS, Vita JA. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation 2011;124:444-453,
8. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwyn AP, Ganz P. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995;75:71B-74B
9. McLenachan JM, Vita J, Fish DR, Treasure CB, Cox DA, Ganz P, Selwyn AP. Early evidence of endothelial vasodilator dysfunction at coronary branch points. Circulation 1990;82:1169-1173.
10. Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation 1994;90:5-11. (Pubitemid 24203655)
11. Okumura K, Yasue H, Matsuyama K, Ogawa H, Morikami Y, Obata K, Sakaino N. Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. J Am Coll Cardiol 1992;19:752-758.
12. Lavi S, Bae JH, Rihal CS, Prasad A, Barsness GW, Lennon RJ, Holmes DRJr, Lerman A. Segmental coronaryendothelial dysfunctioninpatientswith minimal atherosclerosis is associated with necrotic core plaques. Heart 2009;95:1525-1530.
13. Choi B-J, Prasad A, Gulati R, Best PJ, Lennon RJ, Barsness GW, Lerman LO, Lerman A. Coronary endothelial dysfunction in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque. Eur Heart J 2013;34: 2047-2054.
14. Waxman S. Near-infrared spectroscopy for plaque characterization. J Interv Cardiol 2008;21:452-458.
15. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC, Selwyn AP. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-1241.
16. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A. Effects of the direct lipoprotein-associated phospholipase a(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-1182.
17. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32: 2045-2051.